Stock Track | Junshi Biosciences Soars 5.39% as Key Drug Added to National Insurance List

Stock Track11-29

Shares of Junshi Biosciences surged 5.39% in intraday trading on Friday, outperforming the broader market. The stock's rally came after the company's key cancer drug toripalimab injection was successfully included in Category B of China's national drug list for basic medical insurance.

Toripalimab is Junshi's leading immuno-oncology drug, and its inclusion in the national insurance list is seen as a significant milestone for the company. This move will make the drug more affordable and accessible to a broader patient population in China, potentially boosting sales and revenue for Junshi.

The addition of toripalimab to the national insurance list underscores the drug's clinical value and the recognition of Junshi's innovative capabilities in the biopharmaceutical industry. As a result, investors have become more optimistic about the company's growth prospects, driving the stock's impressive rally on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148201103?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-29 11:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148201103","market":"hk","top_or_hot":-1,"title":"Stock Track | Junshi Biosciences Soars 5.39% as Key Drug Added to National Insurance List","media":"Stock Track","content":"<p>Shares of Junshi Biosciences surged 5.39% in intraday trading on Friday, outperforming the broader market. The stock's rally came after the company's key cancer drug toripalimab injection was successfully included in Category B of China's national drug list for basic medical insurance.</p>\n\n<p>Toripalimab is Junshi's leading immuno-oncology drug, and its inclusion in the national insurance list is seen as a significant milestone for the company. This move will make the drug more affordable and accessible to a broader patient population in China, potentially boosting sales and revenue for Junshi.</p>\n\n<p>The addition of toripalimab to the national insurance list underscores the drug's clinical value and the recognition of Junshi's innovative capabilities in the biopharmaceutical industry. As a result, investors have become more optimistic about the company's growth prospects, driving the stock's impressive rally on Friday.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Junshi Biosciences Soars 5.39% as Key Drug Added to National Insurance List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Biosciences Soars 5.39% as Key Drug Added to National Insurance List\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-29 11:28 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Junshi Biosciences surged 5.39% in intraday trading on Friday, outperforming the broader market. The stock's rally came after the company's key cancer drug toripalimab injection was ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1148201103","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148201103","pubTimestamp":1732850921,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Junshi Biosciences surged 5.39% in intraday trading on Friday, outperforming the broader market. The stock's rally came after the company's key cancer drug toripalimab injection was successfully included in Category B of China's national drug list for basic medical insurance.Toripalimab is Junshi's leading immuno-oncology drug, and its inclusion in the national insurance list is seen as a significant milestone for the company. This move will make the drug more affordable and accessible","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"个股赛道君实生物大涨5.39%关键药加入国保名单","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Shares of Junshi Biosciences surged 5.39% in intraday trading on Friday, outperforming the broader market. The stock's rally came after the company's key cancer drug toripalimab injection was successfully included in Category B of China's national drug list for basic medical insurance.\nToripalimab is Junshi's leading immuno-oncology drug, and its inclusion in the national insurance list is seen as a significant milestone for the company. This move will make the drug more affordable and accessible to a broader patient population in China, potentially boosting sales and revenue for Junshi.\nThe addition of toripalimab to the national insurance list underscores the drug's clinical value and the recognition of Junshi's innovative capabilities in the biopharmaceutical industry. As a result, investors have become more optimistic about the company's growth prospects, driving the stock's impressive rally on Friday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148201103"}